Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer
TM Totiger, S Srinivasan, VR Jala, P Lamichhane… - Molecular cancer …, 2019 - AACR
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy and is highly
resistant to standard treatment regimens. Targeted therapies against KRAS, a mutation …
resistant to standard treatment regimens. Targeted therapies against KRAS, a mutation …
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses among all
malignancies. PI3K/AKT/mTOR signaling pathway, a main downstream effector of KRAS is …
malignancies. PI3K/AKT/mTOR signaling pathway, a main downstream effector of KRAS is …
[HTML][HTML] Targeting PI3K pathway in pancreatic ductal adenocarcinoma: rationale and progress
Simple Summary Pancreatic cancer has a dismal 5-year survival rate of 10%, making it one
of the deadliest forms of malignancy. The poor prognosis associated with this disease is …
of the deadliest forms of malignancy. The poor prognosis associated with this disease is …
[HTML][HTML] Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?
K Thillai, H Lam, D Sarker, CM Wells - Oncotarget, 2017 - ncbi.nlm.nih.gov
The development of personalised therapies has ushered in a new and exciting era of cancer
treatment for a variety of solid malignancies. Yet pancreatic ductal adenocarcinoma (PDAC) …
treatment for a variety of solid malignancies. Yet pancreatic ductal adenocarcinoma (PDAC) …
The efficacy of a novel, dual PI3K/mTOR inhibitor NVP‐BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer
N Awasthi, PL Yen, MA Schwarz… - Journal of cellular …, 2012 - Wiley Online Library
Gemcitabine has limited clinical benefits for pancreatic ductal adenocarcinoma (PDAC). The
phosphatidylinositol‐3‐kinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) …
phosphatidylinositol‐3‐kinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) …
[HTML][HTML] A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion
AM Butler, MLS Buzhardt, E Erdogan, S Li, KS Inman… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Pancreatic cancer is highly resistant to current chemotherapies. Identification of the critical
signaling pathways that mediate pancreatic cancer transformed growth is necessary for the …
signaling pathways that mediate pancreatic cancer transformed growth is necessary for the …
Targeting the Akt/PI3K signaling pathway as a potential therapeutic strategy for the treatment of pancreatic cancer
The phosphoinositide 3 kinase AKT mammalian target of rapamycin (PI3K-AKTmTOR)
signaling pathway is an important in the aetiology of pancreatic cancer (PC) and is …
signaling pathway is an important in the aetiology of pancreatic cancer (PC) and is …
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice
CYC Wu, ES Carpenter, KK Takeuchi, CJ Halbrook… - Gastroenterology, 2014 - Elsevier
Background & Aims New drug targets are urgently needed for the treatment of patients with
pancreatic ductal adenocarcinoma (PDA). Nearly all PDAs contain oncogenic mutations in …
pancreatic ductal adenocarcinoma (PDA). Nearly all PDAs contain oncogenic mutations in …
Targeting phosphoinositide 3-kinase pathways in pancreatic cancer-from molecular signalling to clinical trials
Pancreatic cancer has one of the poorest prognoses among all cancers partly because of its
silent nature and tendency for late discovery but also because of its persistent resistance to …
silent nature and tendency for late discovery but also because of its persistent resistance to …
[HTML][HTML] Phosphoinositide 3-kinase signaling pathway in pancreatic ductal adenocarcinoma progression, pathogenesis, and therapeutics
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized
by its sudden manifestation, rapid progression, poor prognosis, and limited therapeutic …
by its sudden manifestation, rapid progression, poor prognosis, and limited therapeutic …